Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface.
In response to the dual challenges of increasingly risky target portfolios and realignment of traditional pharmaceutical company resources away from early-phase research and development (R&D), research groups have sought to engage across the industrial and not-for-profit divide, resulting in the emergence of many different collaborative models. Here, we describe two successful collaborations based upon shared commitment and risk. The risks and complexities of external collaboration can be mitigated by appropriate agreements and tools, but we found that it remains essential that the collaborating scientists adopt a collaborative mindset and embrace the diverse ways of working of partner organizations.
Oncology iMed Chemistry, AstraZeneca, Mereside, Alderley Park, Macclesfield, SK10 4TF, UK. Electronic address: david.andrews@astrazeneca.com.
David M
DM
Andrews
Cancer Research Technology, Jonas Webb Building, Babraham Research Campus, Cambridge, CB22 3AT, UK.
Martin E
ME
Swarbrick
Centre for Therapeutics Discovery, MRC Technology, 1-3 Burtonhole Lane, Mill Hill, London, NW7 1AD, UK.
Andrew T
AT
Merritt
D035843:Biomedical Research / Q000458:organization & administration*; D002626:Chemistry, Pharmaceutical; D003299:Cooperative Behavior; D055808:Drug Discovery; D004345:Drug Industry; D012306:Risk; D014495:Universities